Mesothelioma epidemiology and demographics
|
Mesothelioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mesothelioma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Mesothelioma epidemiology and demographics |
|
Risk calculators and risk factors for Mesothelioma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fatima Shaukat, MD [2]Parminder Dhingra, M.D. [3], Sujit Routray, M.D. [4]
Overview
Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura. The incidence of mesothelioma is estimated to be 3,000 cases annually. The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States. Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1. The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively. There is no racial predilection to mesothelioma.
Epidemiology and Demographics
Prevalence
- Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura.[1]
Incidence
- The incidence of mesothelioma is estimated to be 3,000 cases annually.[2]
- The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States.[3]
- The incidence of pleural mesothelioma is approximately 1.2 per 100,000 individuals in Canada.[3]
- The incidence of mesothelioma has decreased over several decades in the United States coincident with diminishing occupational asbestos exposure and has remained stable since 2003.[4]
Age
- Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1.[1]
- The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively.[4]
Race
- There is no racial predilection to mesothelioma.[1]
References
- ↑ 1.0 1.1 1.2 Epidemiology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016
- ↑ Philip A. Rascoe, Xiaobo X. Cao and W. Roy Smythe (2012). Molecular Pathogenesis of Malignant Pleural Mesothelioma, Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, Dr Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, Available from: http://www.intechopen.com/books/mesotheliomas-synonyms-and-definition-epidemiology-etiology-pathogenesis-cyto-histopathological-features-clinic-diagnosis-treatment-prognosis/molecular-pathogenesis-of-malignant-pleural-mesothelioma
- ↑ 3.0 3.1 Saint-Pierre, Mathieu D.; Pease, Christopher; Mithoowani, Hamid; Zhang, Tinghua; Nicholas, Garth A.; Laurie, Scott A.; Wheatley-Price, Paul (2015). "Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy". Lung Cancer International. 2015: 1–7. doi:10.1155/2015/590148. ISSN 2090-3197.
- ↑ 4.0 4.1 Thomas, Anish; Chen, Yuanbin; Yu, Tinghui; Gill, Ammara; Prasad, Vinay (2015). "Distinctive clinical characteristics of malignant mesothelioma in young patients". Oncotarget. 6 (18): 16766–16773. doi:10.18632/oncotarget.4414. ISSN 1949-2553.